Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444363 | 0.85 | MET (0.70) | METKCNH2 | |
| SCHEMBL2450025 | 0.81 | MET (0.83) | METKCNH2 | |
| SCHEMBL2450362 | 0.81 | MET (0.98) | METKCNH2 | |
| SCHEMBL2449644 | 0.81 | MET (0.79) | METKCNH2 | |
| SCHEMBL2445234 | 0.80 | MET (1.00) | METKCNH2 | |
| SCHEMBL2325612 | 0.79 | MET (1.00) | METKCNH2 | |
| SCHEMBL2326077 | 0.79 | MET (1.00) | METKCNH2 | |
| SCHEMBL2450745 | 0.79 | MET (0.81) | METKCNH2 | |
| SCHEMBL2449306 | 0.78 | MET (0.77) | METKCNH2 | |
| SCHEMBL2447015 | 0.77 | MET (0.75) | METKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896421-B1 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | claimed |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MERCK SHARP & DOHME LLC | 2009-08-06 | — | — | US | claimed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20060293358-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2006-12-28 | — | — | US | claimed |
| US-8207186-B2 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207186-B2 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207186-B2 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1896421-B1 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1896421-B1 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MERCK SHARP & DOHME LLC | 2009-08-06 | — | — | US | disclosed |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MERCK SHARP & DOHME LLC | 2009-08-06 | — | — | US | disclosed |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MERCK SHARP & DOHME LLC | 2009-08-06 | — | — | US | disclosed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2007002254-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293358-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293358-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, RET | MET 4/4885KCNH2 3777/4885 |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MET, RET, ERBB2 | MET 1/4885KCNH2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.